• image

    There's no insulin

    like your own

  • image

    Intralymphatic immunotherapy

    with retogatein (rhGAD65)

    VIDEO

Press Releases 

Events & Mediawatch 

 July 28, 2026   Sweden

Events & Mediawatch 

 July 1, 2026   Sweden

Events & Mediawatch 

 June 25, 2026   Sweden

Events & Mediawatch 

 June 5, 2026   Sweden

Events & Mediawatch 

 May 26, 2026   Sweden

Company Presentation

 March 26, 2026
Download PDF

Calendar

 Dates for financial information and other events
Data pager
Data pager
12
October 7, 2026
Year-end Report
Year-end Report 2025/2026
December 3, 2026
Annual General Meeting
Annual General Meeting 2026
January 26, 2027
Interim report Q1
Interim report Q1 2026/27
April 27, 2027
Interim report Q2
Interim report Q2 2026/27
June 29, 2027
Interim report Q3
Interim report Q3 2026/27
October 26, 2027
Year-end report
Year-end report 2026/27

Manufacturing site in Umeå

Image
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine retogatein (rhGAD65), an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on baculovirus-insect cell expression system.

THE COMPANY

Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes.
The share is traded on Nasdaq First North Growth Market (ticker: DMYD B).


Read More
  • Read more

    Type 1 Diabetes

    Type 1 diabetes is a chronic progressive autoimmune disease where the immune system attacks and breaks down the insulin-producing cells in the pancreas. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 %.

  • Read more

    Pipeline

    Retogatein (rhGAD65/alum) is an investigational antigen-specific immunotherapy for the prevention and treatment of type 1 diabetes. Currently in Phase 3 clinical trials, retogatein has earned Fast Track designation and Orphan Drug Designation from the US FDA.

  • Read more

    Clinical Trials

    The efficacy of retogatein (rhGAD65/alum) is being confirmed in the first ever precision medicine Phase 3 trial in individuals with Stage 3 type 1 diabetes, DIAGNODE-3. The safety and feasibility of retogatein in individuals with Stage 1 or Stage 2 type 1 diabetes is evaluated in the Phase 2 trial, DiaPrecise.

Order GAD for preclinical research

ORDER

CorporaCorte Website Disclaimer
This website is intended for informational purposes only and is designed to provide corporate and investor-related information about Diamyd Medical globally. It is not intended for promotional purposes or to provide medical or healthcare advice.

Annual Report

  December 2, 2025
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research